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IMPORTANCE Randomized clinical trials have demonstrated a substantial benefit of adding
everolimus to endocrine therapy. Everolimus inhibits themammalian target of rapamycin
complex 1 (mTORC1) complex but not mTORC2, which can set off an activating feedback loop
via mTORC2. Vistusertib, a dual inhibitor of mTORC1 andmTORC2, has demonstrated broad
activity in preclinical breast cancer models, showing superior activity to everolimus.
OBJECTIVE To evaluate the safety and efficacy of vistusertib in combination with fulvestrant
compared with fulvestrant alone or fulvestrant plus everolimus in postmenopausal women
with estrogen receptor–positive advanced or metastatic breast cancer.
DESIGN, SETTING, AND PARTICIPANTS TheMANTA trial is an open-label, phase 2 randomized
clinical trial in which 333 patients with estrogen receptor–positive breast cancer progressing
after prior aromatase inhibitor treatment underwent randomization (2:3:3:2) between April 1,
2014, and October 24, 2016, at 88 sites in 9 countries: 67 patients were assigned to receive
fulvestrant, 103 fulvestrant plus vistusertib daily, 98 fulvestrant plus vistusertib
intermittently, and 65 fulvestrant plus everolimus. Treatment was continued until disease
progression, development of unacceptable toxic effects, or withdrawal of consent. Analysis
was performed on an intention-to-treat basis.
INTERVENTIONS Fulvestrant alone or in combination with vistusertib (continuous or
intermittent dosing schedules) or everolimus.
MAIN OUTCOMES ANDMEASURES The primary end point was progression-free survival (PFS).
RESULTS Among the 333 women in the study (median age, 63 years [range, 56-70 years]),
median PFS was 5.4months (95% CI, 3.5-9.2 months) with fulvestrant, 7.6 months (95% CI,
5.9-9.4months) with fulvestrant plus daily vistusertib, 8.0months (95% CI, 5.6-9.9months)
with fulvestrant plus intermittent vistusertib, and 12.3 months (95% CI, 7.7-15.7 months) with
fulvestrant plus everolimus. There was no significant difference in PFS between those
receiving fulvestrant plus daily or intermittent vistusertib and fulvestrant alone (hazard ratio,
0.88 [95% CI, 0.63-1.24]; P = .46; and hazard ratio, 0.79 [95% CI, 0.55-1.12]; P = .16).
CONCLUSIONS AND RELEVANCE The combination of fulvestrant plus everolimus demonstrated
significantly longer PFS compared with fulvestrant plus vistusertib or fulvestrant alone.
The trial failed to demonstrate a benefit of adding the dual mTORC1 andmTORC2 inhibitor
vistusertib to fulvestrant.
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R esistance to endocrine therapy remains a major clini-cal challenge in women with hormone receptor–positive advancedormetastatic breast cancer. There is
increasing evidence that aberrant signaling through thephos-
phatidylinositol 3-kinase (PI3K)–mammalian target of rapa-
mycin (mTOR) signaling pathwayplays a critical role in endo-
crine resistance.1 Approximately 50% of estrogen receptor
(ER)–positive primary breast cancers show abnormal intrin-
sic activation of the PI3K-mTOR pathway and many patients
with advanced or metastatic breast cancer develop acquired
upregulation of PI3K-mTOR signaling.2-4
Preclinical investigation demonstrates that inhibition of
mTOR can overcome endocrine resistance.5-9 Clinical trials
have demonstrated a substantial benefit of adding themTOR
inhibitor everolimus to endocrine agents, especially in endo-
crine-resistant breast cancer.10-12 Everolimus is indicated for
the treatment of hormone receptor–positive, ERBB2/HER2-
negative advancedbreast cancer in combinationwithexemes-
tane in postmenopausal women without symptomatic vis-
ceral disease after recurrence or progression after treatment
with a nonsteroidal aromatase inhibitor (AI).
The mTOR kinase forms 2 distinct multiprotein com-
plexes,mammalian target of rapamycin complex 1 (mTORC1)
andmTORC2.Current clinicalmTORinhibitors suchaseveroli-
mus inhibit the mTORC1 complex only through an indirect
mechanism that doesnot involve themTORkinase, and there
is increasing evidence that thismechanism sets off a negative
feedback loop leading to theactivationofmTORC2,AKTphos-
phorylation, and ultimately treatment resistance.13 Preclini-
cal studies have demonstrated that rapamycin analogues are
unable to completely abrogate mTORC1 signaling and the re-
sidual activity of the downstream effector 4E-BP1 can con-
tinue to initiate protein translation.14Mammalian target of ra-
pamycinkinase inhibitorshavebeendeveloped toenhance the
antitumor activity through more complete TORC1 inhibition
and abrogating AKT-mediated TORC2 activation.
Vistusertib (AZD2014) is a dual inhibitor of bothmTORC1
andmTORC2 complexes15; comparedwith everolimus, vistu-
sertibhasdemonstratedmore completegrowth inhibitionand
celldeath invitroand invivobasedonagreater inhibitory func-
tionagainstmTORC1andadditional inhibitionofmTORC2, es-
pecially in ER-positive breast cancer models.16
Most preclinical and clinical applications of PI3K inhibi-
tors or mTOR inhibitors use continuous daily dosing sched-
ules. However, high-dose pulsatile administration has been
proposed as a way to induce more complete suppression of
mTORsignaling tomaximize therapeutic benefitwhile reduc-
ing toxic effects by allowing for recovery of nontarget tissues
duringdosingbreaks.17,18Using intermittent dosing (2dayson
and 5 days off), vistusertib induced rapid tumor regression in
preclinicalmodels.16The shorterhalf-lifeof vistusertib (mean,
3.3 hours) comparedwith othermTOR inhibitors enables pul-
satile administration of themedication. Themaximum toler-
ated doses for both continuous daily and intermittent dosing
of vistusertibwas established inphase 1 studieswith substan-
tial antitumor activity demonstrated for both schedules.16
The MANTA trial evaluated whether the addition of vis-
tusertib (AZD2014) increases progression-free survival (PFS)
andothermeasuresofantitumoractivityof fulvestrant inpost-
menopausal women with ER-positive advanced or meta-
staticbreast cancerwhohave failedprior therapywithAIs.The
study also evaluatedwhether dual inhibition ofmTORC1 and
mTORC2 with vistusertib leads to improved efficacy com-
paredwithmTORC1 inhibitionwith everolimus and explored
whether high-dose pulsatile dosing of vistusertib can in-
crease the activity and/or improve tolerability comparedwith
continuous daily treatment.
Methods
Study Design and Participants
In the MANTA trial, an investigator-led, open-label, random-
ized phase 2 trial, patients were recruited between April 1,
2014, and October 24, 2016, in 88 centers in the United
Kingdom, Spain, Germany, South Korea, France, Portugal,
Hungary, Romania, and Georgia (trial protocol in Supple-
ment 1). Postmenopausal women with ER-positive, locally
advanced or metastatic breast cancer were eligible if they
either relapsed while undergoing or within 12 months of the
end of adjuvant treatment with an AI or progressed on treat-
ment with an AI. Any number of lines of hormonal therapy
were allowed and AI therapy did not have to be the last treat-
ment prior to randomization. Prior chemotherapy in the
adjuvant or neoadjuvant setting and 1 line of prior chemo-
therapy for metastatic disease were allowed. Measurable or
evaluable disease according to Response Evaluation Criteria
in Solid Tumors, version 1.1 (RECIST 1.1)19 and adequate
hematologic, hepatic, and renal function, and an Eastern
Cooperative Oncology Group performance status of 0 to 2
were required. Patients with life-threatening metastatic vis-
ceral disease, active or treated brain metastases, significant
pulmonary dysfunction, significant cardiac disease, QT pro-
longation, type 1 diabetes or uncontrolled type 2 diabetes,
and previous treatment with fulvestrant, exemestane,
mTOR, PI3K, or AKT inhibitors were excluded. All patients
provided written informed consent. The relevant institu-
tional review boards and ethics committees for the 88 par-
ticipating centers approved the study, which was conducted
Key Points
Question Does the addition of vistusertib increase
progression-free survival and other measures of antitumor activity
of fulvestrant in postmenopausal womenwith estrogen
receptor–positive advanced or metastatic breast cancer that
progressed after prior therapy with aromatase inhibitors?
Findings This randomized clinical trial in 333 patients failed to
demonstrate a benefit of vistusertib plus fulvestrant vs fulvestrant
alone. In addition, the outcomes in both vistusertib groups were
inferior to those in the group treated with fulvestrant plus
everolimus.
Meaning The results suggest that dual mammalian target of
rapamycin inhibition with vistusertib at themaximal tolerated
doses is inferior to mammalian target of rapamycin complex 1
inhibition with the rapamycin analogue everolimus.
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in accordance with the principles of Good Clinical Practice,20
the provisions of the Declaration of Helsinki,21 and other
applicable local regulations. The Barts Experimental Cancer
Medicine Centre had overall responsibility for trial manage-
ment; the Trial Management Group was responsible for day-
to-day running of the trial, and the trial was overseen by an
independent trial steering committee. Safety data were
reviewed regularly by the trial steering committee and an
independent data monitoring committee.
Randomization
Patients were randomized via Interactive Web Response Sys-
tem (2:3:3:2) to receive fulvestrant, fulvestrant plus vistu-
sertib (daily or intermittent), or fulvestrant plus everolimus,
respectively. Computer-generated permuted blocks were
used with stratification by disease measurability and previ-
ous sensitivity to endocrine therapy, defined as at least 24
months of endocrine therapy before recurrence in the adju-
vant setting, complete or partial response to prior metastatic
endocrine treatment, or stabilization for at least 24 weeks of
endocrine therapy for advanced disease.
Procedures
Fulvestrant was given as a 500-mg intramuscular injection
loading dose on day 1, followed by 500-mg injections on
days 15 and 29. Thereafter, 500-mg intramuscular injections
were given every 28 days. Everolimus was given orally once
daily at a dose of 10 mg. The continuous daily schedule of
vistusertib was given orally twice daily at a dose of 50 mg.
Intermittent vistusertib was given orally twice daily on days
1 and 2 of every week at a dose of 125 mg. Treatment was
continued until disease progression, unacceptable toxic
effects, or withdrawal of consent. The protocol provided
detailed guidelines for dose interruptions or reductions for
vistusertib and everolimus; dose adjustments for fulvestrant
followed local guidelines.
The primary end point was PFS based on results of radio-
graphic studies assessedby the local investigators,with inde-
pendent central assessment on a subset of patients. Progres-
sion-free survivalwas defined as time from randomization to
disease progression or death from any cause, whichever oc-
curred first. Secondary end points included overall survival
(OS), objective response rate, clinical benefit rate, duration of
response, clinical benefit, and safety.
TumorassessmentwithRECIST 1.1 includedcomputed to-
mography scanning or magnetic resonance imaging of the
chest, abdomen, and pelvis at baseline, every 8weeks during
the first 40 weeks, and every 12 weeks thereafter until dis-
ease progression. Patients who discontinued 1 or both study
treatments for any reason other than progression of disease
were required to follow the same schedule of assessmentsun-
til progression.
Patients were monitored for adverse events (AEs) and
changes in laboratory test values, electrocardiogram results,
andphysicalexaminationfindings.Adverseeventsweregraded
according to National Cancer Institute Common Toxicity
Criteria (version 4.03)22 and coded with the Medical Diction-
ary for Regulatory Activities.23
Statistical Analysis
Sample size was based on detecting an improvement in me-
dian PFS from 3.7 to 11.1 months (hazard ratio [HR], 0.40) in
patients allocated to receive fulvestrant plus vistusertib (ana-
lyzed separately for each schedule) compared with fulves-
trantalone, anddetectingan improvement inmedianPFS from
7.4 to 11.1 months (HR, 0.67) in patients allocated to receive
fulvestrant plus vistusertib compared with fulvestrant plus
everolimus. With a minimum follow-up of 18 months, a 5%
significance level (1-sided), and 99%power, a total of 130 PFS
events in the fulvestrant plus vistusertib and fulvestrant
comparison were needed for the principal analysis. For the
comparison of fulvestrant plus vistusertib vs fulvestrant
plus everolimus, 120 PFS events were needed based on a
follow-upof 18months, a 10%significance level (1-sided), and
80% power.
Principal efficacy analyses included all randomized pa-
tients on an intention-to-treat basis, with patients analyzed
according to the treatment group towhich theywere random-
ized. Survival endpointswere showngraphicallywithKaplan-
Meier plots, and treatment comparisons were made with the
log-rank test. Hazard ratios were obtained from Cox propor-
tional hazards regression models, with HRs of less than 1
favoring fulvestrant plus vistusertib in the comparison with
fulvestrant alone, and fulvestrant plus everolimus in the com-
parison with fulvestrant plus vistusertib.
Safety analyses includedall patientswho received at least
1 dose of trial treatment. The worst grade of AE during trial
treatmentwas reportedandcomparedwithFisher exact tests.
All prespecified toxic effects and any Medical Dictionary for
Regulatory Activities–coded event satisfying predefined cri-
teria are presented.
Results
BetweenApril 1, 2014, andOctober 24, 2016, 333 patients un-
derwent randomization (Figure 1): 67 patients were assigned
to receive fulvestrant, 103 fulvestrantplusvistusertibdaily, 98
fulvestrant plus vistusertib intermittently, and 65 fulvestrant
plus everolimus. Baseline distributions of patient and tumor
characteristics were similar in the treatment groups (eTable 1
in Supplement 2). Median age was 63 years; 202 of 326 pa-
tientshadvisceral involvement (62.0%)and254of326 (77.9%)
hadmeasurable disease. A total of 103 of 325 patients (31.7%)
hadmetastases in at least 3 organs andmost patients had re-
ceived systemic therapy for metastatic breast cancer. A total
of 282 of 326 patients (86.5%) had previous sensitivity to en-
docrine therapy.
At the cutoff date (October 13, 2017), 43 patients (12.9%)
were still receiving study treatment: 25 of 196 (12.8%) in the
fulvestrant plus vistusertib groups, 11 of 64 (17.2%) in the ful-
vestrant plus everolimus group, and 7of 66 (10.6%) in the ful-
vestrant alone group (eTable 1 in Supplement 2). Ahigher per-
centage of patients in the 3 combination groups discontinued
study treatment becauseofAEsorwithdrawal of consent (ful-
vestrantplusdailyvistusertib, 18of 101 [17.8%]; fulvestrantplus
intermittent vistusertib, 16 of 95 [16.8%]; and fulvestrant plus
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everolimus, 12 of 64 [18.8%]) comparedwith patients treated
with fulvestrant alone (6 of 66 [9.1%]),withno significant dif-
ferences between the combination groups. Treatment adher-
encewas comparablebetween the3 combinationgroups,with
3% to 5% of Investigational Medicinal Product doses being
missed and 28.4% to 33.7% of patients (fulvestrant plus daily
vistusertib, 34of 101 [33.7%]; fulvestrantplus intermittentvis-
tusertib, 27 of 95 [28.4%]; and fulvestrant plus everolimus, 21
of 64 [32.8%]) requiring at least 1 dose reduction of vistu-
sertib or everolimus.
Frequency of AEs (any grade) and severe AEs (grade 3 or
4) was higher in patients assigned to the combination groups
than in those assigned to receive fulvestrant alone (eTable 2
in Supplement 2). The most common grade 3 or 4 AEs in the
combination groups were stomatitis (12 of 92 [13.0%] in vis-
tusertib daily group vs 4 of 92 [4.3%] in vistusertib intermit-
tent group vs 7 of 60 [11.7%] in everolimus group), rash (19 of
92 [20.7%] vs 4 of 92 [4.3%] vs 3 of 60 [5.0%]), asthenia (2 of
92 [2.2%] vs 5 of 92 [5.4%] vs 2 of 60 [3.3%]), diarrhea (2 of 92
[2.2%] vs 5 of 92 [5.4%] vs 1 of 60 [1.7%]), hyperglycemia (4 of
92 [4.3%] vs 3 of 92 [3.3%] vs 2 of 60 [3.3%]), infection (5 of
92 [5.4%] vs 1 of 92 [1.1%] vs 4 of 60 [6.7%]), dyspnea (3 of 92
[3.3%] vs0%vs0%), andnausea (0%vs 3 of 92 [3.3%] vs0%).
Intermittent dosing of vistusertibwas associatedwith a lower
rate of rash or stomatitis but a higher rate of nausea and vom-
iting than daily dosing of vistusertib.
After a median follow-up in all patients of 17.1 months
(95% CI, 15.9-18.3 months), 255 progression events were re-
ported: 57 in patients assigned to fulvestrant, 81 in those
assigned to fulvestrant plus vistusertib daily, 72 in those as-
signed to fulvestrant plus vistusertib intermittently, and45 in
patients assigned to fulvestrant plus everolimus.
Median PFS in patients assigned to fulvestrant alone was
5.4months (95%CI, 3.5-9.2months), 7.6months (95%CI, 5.9-
9.4months) in those assigned to fulvestrant plus daily vistu-
sertib, 8.0 months (95% CI, 5.6-9.9 months) in those as-
signed to fulvestrant plus intermittent vistusertib, and 12.3
months (95%CI, 7.7-15.7months) in those assigned to fulves-
trant plus everolimus (Table). No significant difference in PFS
was seen between the patients assigned to receive fulves-
trant plus daily vistusertib and those who received fulves-
trant alone (HR, 0.88 [95% CI, 0.63-1.24]; log-rank P = .46),
Figure 1. CONSORTDiagram
430 Patients screened
333 Randomized
103 Assigned to fulvestrant plus daily
vistusertib
98 Assigned to fulvestrant plus 
intermittent vistusertib
65 Assigned to fulvestrant plus 
everolimus
67 Assigned to fulvestrant 
101 Treated with fulvestrant plus
daily vistusertib
95 Treated with fulvestrant plus
intermittent vistusertib
64 Treated with fulvestrant plus 
everolimus
66 Treated with fulvestrant 
11 Still undergoing treatment 14 Still undergoing treatment 7 Still undergoing treatment 11 Still undergoing treatment
90 Discontinued
65 Progression
10 Decision by patient
or investigator
2 Death
8 Adverse events
5 Other
2 Did not start treatment
because they were ineligible
3 Did not start treatment
because they withdrew
consent
1 Did not start treatment
because they withdrew
consent
1 Did not start treatment
owing to poor health
81 Discontinued
57 Progression
12 Decision by patient
or investigator
3 Death
4 Adverse events
5 Other
59 Discontinued
52 Progression
5 Decision by patient
or investigator
1 Adverse events
1 Other
53 Discontinued
37 Progression
7 Decision by patient
or investigator
2 Death
5 Adverse events
2 Other
97 Excluded
21 Clinical laboratory finding 
9 Contraindicated comorbidity
11 No measurable disease 
10 Declined to participate 
8 Poor general health
3 Disease not refractory to aromatase inhibitors
6 LVEF <50%
5 Disease not ER positive, ERBB2/HER2-negative
3 Extensive hepatic metastases
2 QTc prolongation
3 Prohibited concomitant medication
2 >1 Line of prior chemotherapy for metastatic breast cancer
13 Unknown
1 Not postmenopausal
LVEF indicates left ventricular ejection fraction.
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between patients assigned to receive fulvestrant plus inter-
mittent vistusertib and those who received fulvestrant alone
(HR, 0.79 [95% CI, 0.55-1.12]; log-rank P = .16), and between
both fulvestrantplusvistusertibgroups (HR, 1.11 [95%CI,0.81-
1.52]; log-rank P = .52). Progression-free survival was signifi-
cantly longer in patients assigned to fulvestrant plus everoli-
muscomparedwith fulvestrantplusdailyvistusertib (HR,0.63
[95%CI,0.45-0.90; log-rankP = .01) and thoseassigned to ful-
vestrant plus everolimus compared with fulvestrant alone
(HR, 0.63 [95% CI, 0.42-0.92]; log-rank P = .01) (Figure 2).
Inpatientswithmeasurabledisease,objectiveresponserate
onthebasisof localassessmentforpatientsreceivingfulvestrant
alonewas25.0%; for those receiving fulvestrant plusdaily vis-
tusertib,30.4%;for thosereceivingfulvestrantplus intermittent
vistusertib, 28.6%; and for those receiving fulvestrant plus
everolimus, 41.2% (Table). Central assessment showedconsis-
tent results.Mediandurationof response inpatientsassignedto
fulvestrant alonewas 16.7months (95%CI, 10.8-19.3months);
fulvestrantplusdailyvistusertib, 11.8months (95%CI,8.4-13.7
months); fulvestrant plus intermittent vistusertib, 9.4months
(95%CI,5.9-14.5months); andfulvestrantpluseverolimus, 17.6
months (95%CI, 9.1-19.1months).
Overall survival results were relatively immature at the
time of the analysis, with a total of 96 deaths: 36 of 101 pa-
tients (35.6%) in the daily vistusertib group, 26 of 95 patients
(27.4%) in the intermittent vistusertib group, 21 of 66 pa-
tients (31.8%) in the fulvestrant alone group, and 13 of 64 pa-
tients (20.3%) in the fulvestrant plus everolimus group. Sur-
vival was longer in patients assigned to fulvestrant plus
everolimus compared with fulvestrant plus daily vistusertib
(HR,0.49[95%CI,0.28-0.86]; log-rankP = .02).Therewasalso
a trend toward improved OS in patients assigned to fulves-
trant plus everolimus compared with fulvestrant alone (HR,
0.56 [95% CI, 0.28-1.09]; log-rank P = .09).
Discussion
TheMANTA trial is the first trial to our knowledge to compare
a dual mTOR inhibitor with a rapamycin analogue in post-
menopausal women with ER-positive advanced or meta-
staticbreast cancer.The trialdidnotmeet itsprimaryendpoint
and failed to demonstrate a benefit of vistusertib plus fulves-
trant comparedwith fulvestrant alone.Furthermore, bothvis-
tusertibgroupswere inferior to treatmentwith fulvestrantplus
everolimus. As these clinical results are in contrast with the
evidence from in vitro and in vivo preclinical models, show-
ingsubstantial synergistic activitybetweenfulvestrantandvis-
tusertibandalso superior activityofvistusertib comparedwith
everolimus in endocrine-sensitive and -resistant breast can-
cermodels,18 it is important to assesswhat factorsmight have
contributed to the failure of vistusertib in this trial.
All 4 patient groups were well balanced in terms of base-
line patient and disease characteristics (eTable 1 in Supple-
ment 2) and the results of the fulvestrant alone group and the
fulvestrant plus everolimus group are consistent with results
from other clinical trials, making it unlikely that patient se-
lection or possible imbalances are the key driver for the ob-
served results.
Another question iswhether a comparable dose intensity
was maintained across the different treatment groups. How-
ever, given that there was no difference in the median num-
ber and percentage ofmissed treatment days of vistusertib or
everolimus, as well as in the percentage of patients requiring
at least 1 dose reduction of everolimus or vistusertib, or in the
percentage of patients discontinuing treatment for reasons
other thandiseaseprogressionordeath, it seemsunlikely that
the lack of observed activity of vistusertib can be attributed
to differences in treatment adherence and dose intensity.
Instead, the results raise the question whether the se-
lected doses of vistusertib might not have been adequate to
fully exert its established preclinical activity. The doses and
schedules within the MANTA trial were based on the maxi-
mum tolerated doses established in a phase 1 trial of vistu-
sertib and fulvestrant.16 This study used similar criteria for
dose-limiting toxic effects as the dose-finding trials for
everolimus.24-26 Consequently, AE profileswere largely com-
parable between the daily vistusertib group and the everoli-
mus group.
However, given that vistusertib inhibits bothmTORC1and
mTORC2 complexes, a possible explanation could be that the
toxic effect–mandateddoses of vistusertib achievedonly sub-
Table. Primary and Key Secondary Efficacy End Points
End Point
Fulvestrant Plus Daily
Vistusertib (n = 101)
Fulvestrant Plus Intermittent
Vistusertib (n = 95) Fulvestrant (n = 66)
Fulvestrant Plus
Everolimus (n = 64)
PFS, median (95% CI), mo 7.6 (5.9-9.4) 8.0 (5.6-9.9) 5.4 (3.5-9.2) 12.3 (7.7-15.7)
HR vs fulvestrant (95% CI) 0.88 (0.63-1.24) 0.79 (0.55-1.12) NA NA
P value .46 .16 NA NA
HR vs fulvestrant plus everolimus (95% CI) 0.63 (0.45-0.90) 0.71 (0.49-1.01) 0.63 (0.42-0.92) NA
P value .01 .06 .01 NA
Objective response rate, % (95% CI) 30.4 (20.5-41.8) 28.6 (18.8-40.0) 25.0 (14.0-38.9) 41.2 (27.6-55.8)
Clinical benefit rate, % (95% CI) 43.0 (31.9-54.7) 39.0 (28.0-50.8) 38.5 (25.3-53.0) 56.9 (42.2-70.7)
Duration of response median (95% CI), mo 11.8 (8.4-13.7) 9.4 (5.9-14.5) 16.7 (10.8-19.3) 17.6 (9.1-19.1)
Duration of clinical benefit median (95% CI), mo 12.0 (11.8-16.6) 13.4 (11.2-18.9) 16.7 (12.8-20.2) 14.3 (12.2-18.6)
Overall survival median (95% CI), mo 27.1 (20.0-NR) 24.2 (20.6-NR) 24.4 (17.3-NR) NR
Abbreviations: HR, hazard ratio; NA, not applicable; NR, not reached; PFS, progression-free survival.
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optimal inhibition of the mTORC1 complex and that the re-
sidual activity of 4E-BP1 is sufficient to negate a substantial
treatment effect.14 Similar observationshavebeenmadewith
pan-PI3K inhibitors andhaveultimately resulted in thedevel-
opment of α-specific, β-sparing PI3K inhibitors that are cur-
rently in phase 3 trials in a similar indication. Alternative ex-
planations for the observed results could be that inhibition of
themTORC2 complex has limited clinical relevance in breast
cancer and/or that everolimus might have additional effects
independentofmTORC1 inhibition.As thesequestionsarecriti-
cal for the future development of agents of the same class, ef-
forts should bemade to further evaluate the hypothesis. One
way of testing this would be to compare direct target inhibi-
tion and downstream effects in tumor samples, but tissue
samples while patients were undergoing treatment were not
available from the MANTA trial.
As a positive result, the MANTA trial demonstrated that
the combination of fulvestrant plus everolimus significantly
increases PFS comparedwith fulvestrant alone, providing fur-
ther evidenceof thebenefits of everolimus for the treatmentof
postmenopausal women with ER-positive breast cancer after
lossof responsetoAIs.Theobservedbenefits inPFSare remark-
ablysimilartotheresultsofthePrE0102randomizedphase2trial,
which reported that addition of everolimus to fulvestrant im-
provedmedianPFSfrom5.1 to10.3months (HR,0.61;P = .02).27
Asimilarbenefitwasalsoobservedforthecombinationofeveroli-
mus and exemestane in theBOLERO-2 (Breast Cancer Trials of
OralEverolimus–2)phase3 trial.10ThepreliminaryOSdatasug-
gestatrendtowardimprovedOS,butresultsmustbeinterpreted
withcautionas,at thetimeofthisanalysis,only30%oftheover-
all OS events had occurred.
Toourknowledge, theMANTAtrial isalsothefirst trial todi-
rectly compare a continuous daily treatment schedule with a
high-dosepulsatileschedule.Preclinical studieshavesuggested
that intermittent, high-dose treatment might be a means to
achievemorecompletesuppressionofmTORsignalingandcould
Figure 2. Kaplan-Meier Plot of Progression-Free Survival (PFS)
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A, Fulvestrant plus daily vistusertib vs fulvestrant (median PFS: fulvestrant plus
daily vistusertib, 7.6 months; fulvestrant, 5.4 months; hazard ratio, 0.88
[95% CI, 0.63-1.24]; log-rank P = .46). B, Fulvestrant plus everolimus vs
fulvestrant plus daily vistusertib (median PFS: fulvestrant plus everolimus,
12.3 months; fulvestrant plus daily vistusertib, 7.6 months; hazard ratio, 0.63
[95% CI, 0.45-0.90]; log-rank P = .01). C, Fulvestrant plus everolimus vs
fulvestrant (median PFS: fulvestrant plus everolimus, 12.3 months; fulvestrant,
5.4 months; hazard ratio, 0.63 [95% CI, 0.42-0.92]; log-rank P = .01).
D, Fulvestrant plus daily vistusertib vs fulvestrant plus intermittent vistusertib
(median PFS: fulvestrant plus daily vistusertib, 7.6 months; fulvestrant plus
intermittent vistusertib, 8.0months; hazard ratio, 1.11 [95% CI, 0.81-1.52];
log-rank P = .52).
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leadtoanincreaseinapoptosisbutmightalsoimprovethethera-
peutic index.Althoughwedidnotobserve relevantdifferences
in any of the efficacy end points (including response rates) be-
tweenthe2schedules selected for this trial, intermittentdosing
was associatedwith a lower rate of rash or stomatitis (albeit at
thecostofhigher ratesofshort-termnauseaandvomiting), sug-
gestingthat itmightbeof interesttofurtherevaluatethishypoth-
esis in future trials. As the same caveat regarding the effective
vistusertib dose and the degree ofmTORC1 inhibition applies,
thistrialwasultimatelyunabletodefinitivelyanswerthehypoth-
eses around administration of high-dose pulsatile treatment.
Limitations
This trial has some limitations. The main limitations are the
small sample size and the open-label design.
Conclusions
Overall, theMANTAtrialprovides importantevidence thatdual
mTOR inhibition is inferior tomTORC1 inhibitionwith the ra-
pamycin analogue everolimus, possibly as a result of a toxic
effects–mandated compromise in the degree of mTORC1 in-
hibition owing to the simultaneous inhibition of mTORC2.
High-dose intermittent pathway inhibition could not im-
prove the antitumor activity in this randomized trial but was
associated with an improved safety profile and might be fur-
ther evaluated in the future with other agents. The results
presented here do not support further evaluation of vistu-
sertib inER-positivemetastaticbreast cancer, butalso raise im-
portant questions around the future of this class of drugs.
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